Experimental evolution of cefiderocol resistance in Pseudomonas aeruginosa
Cefiderocol is a novel and promising cephalosporin approved for treating severe infections caused by Gram-negative bacteria with limited therapeutic options. One of the primary targets of cefiderocol is Pseudomonas aeruginosa, a significant opportunistic Gram-negative pathogen. In this study, we uti...
Saved in:
Main Authors: | Igor Chebotar, Konstantin Kuleshov, Julia Bocharova, Nikolay Mayanskiy |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-08-01
|
Series: | Heliyon |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844025020675 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The phenomenon of changing aztreonam susceptibility in Pseudomonas aeruginosa during formation of colistin resistance in vitro
by: Bocharova Yu.A., et al.
Published: (2025-03-01) -
Cefiderocol activity against planktonic and biofilm forms of β-lactamase-producing pseudomonas aeruginosa from people with cystic fibrosis
by: Giorgia Fabrizio, et al.
Published: (2025-06-01) -
Cefiderocol susceptibility of Stenotrophomonas maltophilia species complex and carbapenem-resistant Pseudomonas aeruginosa isolates from blood cultures at a university hospital in Tokyo, Japan
by: Wataru Aoki, et al.
Published: (2025-09-01) -
Activity of Cefiderocol and Other New Antibiotics Against Extensively Drug-Resistant <i>Klebsiella pneumoniae</i> Strains
by: E. V. Karpova, et al.
Published: (2023-02-01) -
The Combined Effect of Bacteriophages and Antibiotics on Pseudomonas aeruginosa Biofilm
by: A. S. Gorshkova, et al.
Published: (2020-06-01)